Biogen, headquartered in Cambridge, Massachusetts, specializes in therapies for neurological diseases, employing 7,570 people and offering treatments for conditions like MS, SMA, Alzheimer's, and ALS. Their product portfolio includes TECFIDERA, SPINRAZA, and collaborations on LEQEMBI and others.
BIIB has been in the news recently: Biogen Inc. reported adjusted earnings per share of $5.47 for Q2 2025, exceeding analyst expectations. Over the last three months, analysts have given varied ratings for Biogen, reflecting a mix of optimism and pessimism.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
